KALA

KALA BIO Inc

Add to Watchlist

Advanced Chart

7.160

-0.16(-2.186%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

7.680

Open

7.460

VWAP

7.16

Vol

110.17K

Mkt Cap

46.20M

Low

7.000

Amount

788.50K

EV/EBITDA(TTM)

Total Shares

2.82M

35.63M

EV/OCF(TTM)

P/S(TTM)

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

3 Analyst Rating

81.56% Upside

Wall Street analysts forecast KALA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALA is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

81.56% Upside

Current: 7.160

Low

12.00

Averages

13.00

High

15.00

81.56% Upside

Current: 7.160

Low

12.00

Averages

13.00

High

15.00

Ladenburg

NULL

Buy

initiated

$12

2025-07-11

Reason

Ladenburg

Price Target

$12

2025-07-11

initiated

NULL

Buy

Reason

Ladenburg initiated coverage of Kala Pharmaceuticals with a Buy rating and $12 price target. The company is targeting a $1B-plus orphan ophthalmology market, the analyst tells investors in a research note.

Oppenheimer

Outperform

initiated

$15

2025-06-02

Reason

Oppenheimer

Price Target

$15

2025-06-02

initiated

Outperform

Reason

Oppenheimer assumed coverage of Kala Pharmaceuticals with an Outperform rating and $15 price target, after the company Q1 results with a bottom-line beat and highlighted progress across its pipeline. As Kala remains focused on the development of KPI-012 for rare ocular diseases, the firm is encouraged to see enrollment in the Phase 2b trial for the treatment persistent corneal epithelial defect advancing well. Management still anticipates topline readout in Q3 2025.

H.C. Wainwright

Buy

downgrade

$15 -> $12

2025-05-23

Reason

H.C. Wainwright

Price Target

$15 -> $12

2025-05-23

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Kala Pharmaceuticals to $12 from $15 and keeps a Buy rating on the shares following the Q3 report.

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$15

2025-04-04

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$15

2025-04-04

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$15

2025-02-13

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$15

2025-02-13

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$15

2024-11-15

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$15

2024-11-15

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for KALA BIO Inc (KALA.O) is -1.58, compared to its 5-year average forward P/E of -1.62. For a more detailed relative valuation and DCF analysis to assess KALA BIO Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.62

Current PE

-1.58

Overvalued PE

-0.31

Undervalued PE

-2.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.79

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.72

Undervalued EV/EBITDA

-2.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6.78

Current PS

0.00

Overvalued PS

16.72

Undervalued PS

-3.16